Research Papers:

IL-22 promotes the progression of breast cancer through regulating HOXB-AS5

Jiang Rui _, Zhao Chunming, Gao Binbin, Shao Na, Wang Shengxi and Song Wei

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:103601-103612. https://doi.org/10.18632/oncotarget.22063

Metrics: PDF 1276 views  |   HTML 2265 views  |   ?  


Jiang Rui1, Zhao Chunming2, Gao Binbin1, Shao Na1, Wang Shengxi1 and Song Wei1

1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

2Department of Opthalmology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

Correspondence to:

Jiang Rui, email: [email protected]

Keywords: IL-22, HOXB-AS5, breast cancer, PI3K/AKT/mTOR

Received: August 01, 2017     Accepted: September 23, 2017     Published: October 19, 2017


Interleukin-22 (IL-22) is a well-known tumor related inflammatory factor that is associated with variety of cancers. HOXB-AS5, a long non-coding RNA located in HOX gene clusters, has been elevated in breast cancer (BC) tissues. Herein, IL-22 and HOXB-AS5 were upregulated in the serum and tissues of BC patients and were associated with clinical stages. Furthermore, we also investigated the effects of IL-22-HOXB-AS5 pathway on progression of BC, and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-mTOR pathway. These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22063